Preparing for Parkinson's disease prevention trials: Current progress and future directions
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Preventing Parkinson's disease (PD) progression is challenging due to limitations in current trials. Future success relies on early intervention, advanced biomarkers, and personalized approaches for high-risk individuals.
Area Of Science
- Neuroscience
- Clinical Neurology
- Biomarker Research
Background
- Numerous clinical trials have failed to effectively delay or prevent Parkinson's disease (PD) progression.
- Key limitations include insensitive clinical scales, PD phenotype heterogeneity, and late-stage intervention targeting.
Purpose Of The Study
- To explore new strategies for preventing the onset of clinical Parkinson's disease.
- To highlight the transformative potential of recent advances in biomarker research for PD trials.
Main Methods
- Review of limitations in conventional Parkinson's disease (PD) clinical trials.
- Analysis of emerging biomarker research (tissue, fluid, imaging) for PD.
- Examination of new frameworks for classifying synucleinopathies.
Main Results
- Conventional scales are insufficient for early PD detection; heterogeneity complicates efficacy assessment.
- Biomarker advancements offer improved patient selection, stratification, and monitoring.
- New classification frameworks aid in distinguishing biological subtypes for targeted trials.
Conclusions
- Preventing Parkinson's disease (PD) requires early enrollment of high-risk individuals with personalized, low-risk interventions.
- Biomarkers or sensitive clinical markers are crucial endpoints for successful prevention trials.
- Timely, ethical, and community-aligned trials necessitate early stakeholder involvement.
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
Related Concept Videos
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
The cephalic phase is a conditioned or learned response to familiar foods. Our appetite or desire for a particular food modifies the preparatory responses directed by the brain. Individuals may produce more saliva and stomach...